Immunic, Inc. (IMUX)

NASDAQ: IMUX · IEX Real-Time Price · USD
1.450
-0.015 (-1.02%)
At close: Mar 1, 2024, 4:00 PM
1.430
-0.020 (-1.38%)
After-hours: Mar 1, 2024, 7:55 PM EST
-1.02%
Market Cap 130.40M
Revenue (ttm) n/a
Net Income (ttm) -93.61M
Shares Out 89.93M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 886,455
Open 1.430
Previous Close 1.465
Day's Range 1.420 - 1.545
52-Week Range 0.945 - 3.110
Beta 1.92
Analysts Buy
Price Target 7.00 (+382.76%)
Earnings Date Feb 22, 2024

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Daniel Vitt Ph.D.
Employees 77
Stock Exchange NASDAQ
Ticker Symbol IMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for IMUX stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(382.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

NEW YORK , Feb. 29, 2024 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

3 days ago - PRNewsWire

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Initia...

10 days ago - PRNewsWire

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally admi...

17 days ago - PRNewsWire

Immunic to Participate in Investor and Scientific Conferences in February

NEW YORK , Feb. 1, 2024 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...

4 weeks ago - PRNewsWire

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis , Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes – – Pha...

2 months ago - PRNewsWire

Immunic, Inc. Announces Private Placement of up to $240 Million

NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi...

2 months ago - PRNewsWire

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

– Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual P...

3 months ago - PRNewsWire

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosi...

3 months ago - PRNewsWire

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK , Nov. 7, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally admini...

4 months ago - PRNewsWire

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

4 months ago - PRNewsWire

Immunic to Participate in Scientific and Industry Conferences in November

NEW YORK , Oct. 26, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

4 months ago - PRNewsWire

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

NEW YORK , Oct. 16, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

4 months ago - PRNewsWire

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

NEW YORK , Oct. 15, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

5 months ago - PRNewsWire

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

– Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo – – NfL Effect Consistent With Recently Released Data from Separate, Phase 2...

5 months ago - PRNewsWire

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes  – – NfL Effect in N...

5 months ago - PRNewsWire

Immunic to Participate in Scientific Conferences in October

NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

5 months ago - PRNewsWire

Immunic to Participate in Industry and Investor Conferences in September

NEW YORK , Sept. 6, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

6 months ago - PRNewsWire

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 – –  Full Data Readout Expected in April 2025 – NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnolo...

7 months ago - PRNewsWire

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis – – Positive...

7 months ago - PRNewsWire

Immunic to Participate in Investor and Scientific Conferences in August

NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

7 months ago - PRNewsWire

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK , July 27, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administ...

7 months ago - PRNewsWire

Immunic to Participate in Scientific and Investor Conferences in July

NEW YORK , June 29, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...

8 months ago - PRNewsWire

Immunic to Participate in Scientific and Investor Conferences in June

NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

9 months ago - PRNewsWire

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

– Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator – – Nurr1 Activation Suggested to Prevent Neurodegeneration...

10 months ago - PRNewsWire

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for  a New Therapeutic Approach  to Treat Gastrointestinal Diseases by Promoting Regeneration of B...

10 months ago - PRNewsWire